Comparative Study of Dehydroepiandrosterone versus Femarelle® on Menopausal Systemic and Genitourinary Syndrome
Gynecologic and Obstetric Investigation · 22.06.2026 · 1-10
DOI: 10.1159/000552775 ↗Kurz gefasst
Fachartikel in der Zeitschrift Gynecologic and Obstetric Investigation, online erschienen am 22.06.2026. Verfasst von Cheng-Yu Long und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan. Die Arbeit nennt 72 Literaturangaben.
Abstract (Originalsprache)
Objectives
The aim was to evaluate the therapeutic effects of dehydroepiandrosterone (DHEA) and DT56a (Femarelle®) on systemic and genitourinary symptoms of menopause in postmenopausal women.
Design
A comparative effectiveness research study of seventy postmenopausal women (mean age: 53 years), experiencing postmenopausal symptoms, was designed.
Participants
Seventy patients were randomly assigned to receive either DHEA (60 mg/day) or Femarelle® (644 mg/day) for 3 months. Materials, Setting, Methods: Subjects were assessed for serum estradiol, luteinizing hormone, follicle-stimulating hormone, Greene Climacteric Scales Scores, female urinary symptoms, and female sexual function index (FSFI).
Results
Both DHEA and Femarelle® demonstrated comparable efficacy in reducing total Greene Climacteric Scale scores. No significant differences in serum follicle-stimulating hormone and E2 levels were observed between the 2 groups. Within-group analyses showed that DHEA was associated with significant improvements in urinary symptoms (overactive bladder symptom score, urinary distress inventory-6, incontinence impact questionnaire-7, international consultation of incontinence questionnaire, and pelvic organ prolapse distress inventory) and sexual function measures (FSFI domains including desire, arousal, lubrication, orgasm, and satisfaction), whereas Femarelle® did not show significant changes over the 3-month period. Between-group comparisons of change scores suggested a trend toward greater improvement in the DHEA group; however, these findings should be interpreted with caution, given the exploratory design and limited sample size.
Limitations
The absence of testosterone measurements limits the assessment of the androgenic effects of DHEA. Femarelle® has never been studied for sexual function; our findings are preliminary and require long-term validation.
Conclusions
While both DHEA and Femarelle® were effective in improving climacteric symptoms, DHEA was associated with improvements in genitourinary symptoms in this cohort. However, given the exploratory design and absence of a placebo control, these findings should be interpreted as hypothesis-generating.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
- Department of Obstetrics/Gynecology, Changhua Christian Hospital, Changhua, Taiwan.
- Department of Obstetrics and Gynecology, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, Taiwan.
- Department of Obstetrics and Gynecology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan, nancylin95@gmail.com.
Zitieren
APA
Long, C. Y., Huang, C. C., Chang, C. Y., Loo, Z. X., Feng, C. W., Sung, I. C., & Lin, K. L. (2026). Comparative Study of Dehydroepiandrosterone versus Femarelle® on Menopausal Systemic and Genitourinary Syndrome. Gynecologic and Obstetric Investigation, 1-10. https://doi.org/10.1159/000552775
Vancouver
Long CY, Huang CC, Chang CY, Loo ZX, Feng CW, Sung IC, et al. Comparative Study of Dehydroepiandrosterone versus Femarelle® on Menopausal Systemic and Genitourinary Syndrome. Gynecologic and Obstetric Investigation. 2026:1-10. doi:10.1159/000552775
BibTeX
@article{Long2026,
author = {Long, Cheng-Yu and Huang, Chih-Cheng and Chang, Chieh-Yu and Loo, Zi-Xi and Feng, Chien-Wei and Sung, I-Chieh and Lin, Kun-Ling},
title = {Comparative Study of Dehydroepiandrosterone versus Femarelle® on Menopausal Systemic and Genitourinary Syndrome},
journal = {Gynecologic and Obstetric Investigation},
year = {2026},
pages = {1--10},
doi = {10.1159/000552775}
}
EUVIMED